talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 2016;101:2340–2347.
36 Prabhakar BS, Bahn RS, Smith TJ: Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003;24:802–835.
37 Fruhbeck G, Becceril S, Sainz N Garrastuchu P, Garcia-Vellosa MJ: BAT: a new target for human obesity? Trends Pharmacol Sci 2009;30:387.
38 Drexhage HA: Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves’ disease? Endocrinology 2006;147:9–12.
39 El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L: The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006;154:623–632.
40 Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R, Beck-Peccoz P: Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006;154:511–517.
41 Salvi M, Vannucchi G, Beck-Peccoz P: Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab 2013;98:4291–4299.
42 Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015;100:422–431.
43 Salvi M, Vannucchi G, Campi I, Curr N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P: Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009;131:360–365.
44 Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ: Increased generation of fibrocytes in thyroid associated ophthalmopathy. J Clin Endocrinol Metab 2010;95:430–438.
45 Tomlinson JW, Durrani OPM, Bujalska IJ, Gathercole LL, Tomliss PJ, Reuser TTQ, Rose GE, Curnow SJ, Stewart PM, Walker EA, Rauz S: The role of 11β-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2010;95:398–406.
46 Görtz G-E, Horstmann M, Aniol B, Delos Reyes B, Fandrey J, Eckstein A, Berchner-Pfannschmidt U: Hypoxia-dependent HIF-1 activation impacts on tissue remodeling in Graves’ ophthalmopathy – implications for smoking. J Clin Endocrinol Metab 2016;101:4834–4842.
47 Pappa A, Lawson JM, Calder V, Fells P, Lightman S: T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol 2000;8:517–522.
48 Han R, Smith TJ: Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol 2005;174:3072–3079.
49 Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D: The effects of tumour necrosis factor-alpha and interleukin 1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis. Eur J Endocrinol 2006;155:395–403.
50 Kazim M, Goldberg RA, Smith TJ: Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 2002;120:380–386.
51 Salvi M, Campi I: Medical Treatment of Graves’ Orbitopathy. Horm Metab Res 2015;47:779–788.
52 Afzali B, Lombardi G, Lechler RI, Lord GM: The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32–46.
53 Kahaly GJ, Shimony O, Gellman YN, Lytton SD, Eshkar-Sebban L, Rosenblum N, Refaeli E, Kassem S, Ilany J, Naor D: Regulatory T-cells in graves’ orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin. J Clin Endocrinol Metab 2010;96:422–429.
54 Peng D, Xu B, Wang Y, Guo H, Jiang Y: A high frequency of circulating Th22 and Th17 cells in patients with new onset Graves’ disease. PLoS One 2013;8:e68446.
55 Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF: Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2000;52:267–271.
56 Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG: Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:3464–3470.
57 De Roux N, Polak M, Couet J, et al: A neomutation of the thyroid stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab 1996;81:2023–2026.
58 Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS: A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J Mol Endocrinol 2011;46:155–163.
59 Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R, Ludgate M: Thyrotropin receptor activation increases hyaluronan production in preadipocyte-fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem 2009;284:26447–26455.
60 Kuriyan AE, Phipps RP, O’Loughlin CW, Feldon SE: Improvement of thyroid eye disease following treatment with the cyclooxygenase-2 selective inhibitor celecoxib. Thyroid 2008;18:911–914.
61 Feldon SE, O’Loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP: Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 2006;169:1183–1193.
